

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Tuesday, May 09, 2017 3:25 PM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** BLA 125643 Clinical Data Information Request 5.9.17

**Importance:** High

**Follow Up Flag:** Follow up  
**Due By:** Wednesday, May 10, 2017 10:00 AM  
**Flag Status:** Flagged

Hi Dr. Sproule,

Reference is made to the current BIOTR.xpt file for ZUMA1. There is no column for "Aperiod", and tumor measurements include those performed after retreatment. As with the ADTR.xpt file that required revision, we also note that the "MINSPDFL" flag includes flags for tumor measurements performed after retreatment. For efficacy analysis, submit a revised BIOTR.xpt file that

- a) adds the "Aperiod" column, and
- b) corrects the "MINSPDFL" flag to reflect the first KTE-C19 dose, in accordance with the main analysis plan.

**Please respond by noon Friday May 12, 2017**

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax: 301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."